Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1724000

registered interest
date	29/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gender Dysphoria: Children
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what specific plans they have to introduce legislation on the prescription of puberty blockers for children with gender dysphoria issues, and whether they plan to address the issue of such drugs being brought into England from Northern Ireland using prescriptions by private providers, and from other jurisdictions.
tabling member printed	Baroness Hoey
uin	HL422
answer	answer is ministerial correction date of answer 09/08/2024 answer text <p>The Secretary of State for Health and Social Care is inclined to renew the emergency banning order on puberty blockers with a view to converting it to a permanent ban, subject to appropriate consultation.</p><p>Human medicines and healthcare are transferred matters in respect of Northern Ireland. We are engaging with the Northern Ireland Executive, including on whether the ban should apply across the United Kingdom. We are committed to providing young people with holistic care, in line with the recommendations of the Cass Review.</p> answering member printed Baroness Merron question first answered 09/08/2024 13:42:23 answering member 347 label Biography information for Baroness Merron
tabling member	210 label Biography information for Baroness Hoey

1721322

registered interest
date	17/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gender Dysphoria: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of restricting puberty blockers for the treatment of gender incongruence on the (a) physical and (b) mental health of young trans people.
tabling member constituency	Lancaster and Wyre
tabling member printed	Cat Smith
uin	87
answer	answer is ministerial correction date of answer 29/07/2024 answer text <p>The emergency banning Order, restricting the sale or supply of puberty blockers, was introduced by the previous Government. The Order enables those who were already on a course of treatment with Gonadotrophin-Releasing Hormone Analogues, before 3 June 2024 from a UK based private or National Health Service provider, to continue to have them supplied. Those who were already on a course of treatment prescribed by an EEA or Switzerland registered prescriber can legally switch to a UK based prescriber to continue their treatment.</p><p>The expert Cass Review, which is one of the most comprehensive reviews of gender identity services for children and young people to date, states that the rationale for early puberty suppressing hormones to treat gender dysphoria is unclear and the effects on cognitive and psychosexual development are unknown. This Government will always act in the interests of patient safety, which is why the Secretary of State signalled his intention to renew the Order and consult on a permanent ban (subject to the outcome of the ongoing judicial review).</p><p>We are committed to implementing the recommendations of the Cass Review to ensure that young people presenting to the NHS with gender dysphoria are receiving appropriate and high-quality care. That is why NHS England and the National Institute of Health and Care Research, the research arm of the Department, are working together to commission a study into the potential benefits and harms of puberty suppressing hormones as a treatment option for children and young people with gender incongruence. The study team is now in place and are finalising their application for funding which will be assessed by an independent scientific review study ahead of the commencement of wider approvals, including ethics, and set up.</p><p>We will continue to monitor the impacts of the Order, including on mental health. Professor Louis Appleby, Chair of the National Suicide Prevention Strategy Advisory Group, has examined evidence for a large rise in suicides claimed by campaigners. His paper, which was published on 19 July 2024, concluded that the data do not support the claim that there has been a large rise in suicide in young gender dysphoria patients at the Tavistock clinic.</p><p>Some children and young people may be concerned by these changes. If they are already under the care of a Children and Young People’s mental health provider or the Child and Adolescent Mental Health Services, they can contact their team for advice. If they are not, their general practice team will be able to assess whether further referrals for mental health support are required. Patients can also be signposted to the advice on getting mental health support available on the NHS.UK website. Anyone in need of urgent support can contact NHS 111 and choose the mental health option, option two. Further details are available at the following link:</p><p><a href="https://www.nhs.uk/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/" target="_blank">https://www.nhs.uk/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/</a></p><p>Professor Appleby’s paper is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust-independent-report" target="_blank">https://www.gov.uk/government/publications/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust-independent-report</a></p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne grouped question UIN 109 91 question first answered 29/07/2024 13:55:40 answering member 1506 label Biography information for Andrew Gwynne
tabling member	4436 label Biography information for Cat Smith

1721323

registered interest
date	17/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gender Dysphoria: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department is taking steps to ensure that those proscribed puberty blockers for the treatment of gender incongruence will continue to receive them.
tabling member constituency	Lancaster and Wyre
tabling member printed	Cat Smith
uin	88
answer	answer is ministerial correction date of answer 29/07/2024 answer text <p>The emergency banning order limiting the sale or supply of puberty blockers against private or non-United Kingdom prescriptions allows a child under 18 years old, who was already on a course of treatment with Gonadotrophin-Releasing Hormone Analogues before 3 June 2024 from a UK based private or National Health Service provider, to continue to have them supplied. Those who were already on a course of treatment prescribed by an EEA or Switzerland registered prescriber can legally switch to a UK based prescriber to continue their treatment.</p><p>This government has committed to implementing the expert recommendations of the Cass Review to ensure that young people presenting to the NHS with gender dysphoria are receiving appropriate and high-quality care. That is why NHS England and the National Institue of Health and Care Research – the research arm of the department – are working together to commission a study into the potential benefits and harms of puberty suppressing hormones as a treatment option for children and young people with gender incongruence. The study team is now in place and are finalising their application for funding which will be assessed by an independent scientific review study ahead of the commencement of wider approvals, including ethics, and set up.</p><p>Children and young people unable to access puberty blockers are strongly advised to meet with their clinician. We expect clinicians to be working with impacted patients to consider what the best care for them is going forward. Some children and young people may be concerned by these changes. If they are already under the care of a Children and Young People’s mental health provider or the Child and Adolescent Mental Health Services, they can contact their team for advice. If they are not, their general practice team will be able to assess whether further referrals for mental health support are required. Patients can also be signposted to the advice on getting mental health support available on the NHS.UK website. Anyone in need of urgent support can contact NHS 111 and choose the mental health option, option two. Further details are available at the following link:</p><p><a href="https://www.nhs.uk/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/" target="_blank">https://www.nhs.uk/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/</a></p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 29/07/2024 14:33:23 answering member 1506 label Biography information for Andrew Gwynne
tabling member	4436 label Biography information for Cat Smith

1721324

registered interest
date	17/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gender Dysphoria: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made a comparative assessment of the UK’s position on the prescription of puberty blockers for the treatment of gender incongruence with that of other European countries.
tabling member constituency	Lancaster and Wyre
tabling member printed	Cat Smith
uin	89
answer	answer is ministerial correction date of answer 29/07/2024 answer text <p>The Cass Review is one of the most comprehensive reviews of gender identity services for children and young people to date worldwide.</p><p>The Cass review included an assessment of evidence from other countries and concluded that there was a lack of evidenced-based guidelines and, therefore, limitations for adopting these for National Health Service gender services. Informed by the Cass review, we are now reforming transgender care for young people in this country, based on the best possible evidence. That means a holistic approach, with puberty suppressing hormones only considered within a much broader needs assessment, and only then in the context of a clinical trial. We are committed to implementing the recommendations of the Cass Review, as that is the care model we believe to be the best approach in the interests of patient safety.</p><p>It is simply not possible for pharmacists to check whether prescriptions issued from overseas registered prescribers have been issued in a similarly safe and effective way, and we know that some overseas providers who advertise their services do not follow this approach.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 29/07/2024 14:25:58 answering member 4444 label Biography information for Karin Smyth
tabling member	4436 label Biography information for Cat Smith

1721325

registered interest
date	17/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gender Dysphoria: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what his timetable is for the clinical trial being conducted on the use of puberty blockers for the treatment of gender incongruence.
tabling member constituency	Lancaster and Wyre
tabling member printed	Cat Smith
uin	90
answer	answer is ministerial correction date of answer 29/07/2024 answer text <p>The expert Cass Review, which is one of the most comprehensive reviews of gender identity services for children and young people to date, states that the rationale for early puberty suppressing hormones to treat gender dysphoria is unclear and the effects on cognitive and psychosexual development are unknown. This is why NHS England and the National Institute of Health and Care Research, the research arm of the department, are working together to commission a study into the potential benefits and harms of puberty suppressing hormones as a treatment option for children and young people with gender incongruence. The study team is now in place and are finalising their application for funding which will be assessed by an independent scientific review study ahead of the commencement of wider approvals, including ethics, and set up.</p> answering member constituency Bristol South answering member printed Karin Smyth grouped question UIN 443 question first answered 29/07/2024 14:21:24 answering member 4444 label Biography information for Karin Smyth
tabling member	4436 label Biography information for Cat Smith

1721326

registered interest
date	17/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gender Dysphoria: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential risks of harm being caused by restrictions on puberty blockers for treatments of gender incongruence.
tabling member constituency	Lancaster and Wyre
tabling member printed	Cat Smith
uin	91
answer	answer is ministerial correction date of answer 29/07/2024 answer text <p>The emergency banning Order, restricting the sale or supply of puberty blockers, was introduced by the previous Government. The Order enables those who were already on a course of treatment with Gonadotrophin-Releasing Hormone Analogues, before 3 June 2024 from a UK based private or National Health Service provider, to continue to have them supplied. Those who were already on a course of treatment prescribed by an EEA or Switzerland registered prescriber can legally switch to a UK based prescriber to continue their treatment.</p><p>The expert Cass Review, which is one of the most comprehensive reviews of gender identity services for children and young people to date, states that the rationale for early puberty suppressing hormones to treat gender dysphoria is unclear and the effects on cognitive and psychosexual development are unknown. This Government will always act in the interests of patient safety, which is why the Secretary of State signalled his intention to renew the Order and consult on a permanent ban (subject to the outcome of the ongoing judicial review).</p><p>We are committed to implementing the recommendations of the Cass Review to ensure that young people presenting to the NHS with gender dysphoria are receiving appropriate and high-quality care. That is why NHS England and the National Institute of Health and Care Research, the research arm of the Department, are working together to commission a study into the potential benefits and harms of puberty suppressing hormones as a treatment option for children and young people with gender incongruence. The study team is now in place and are finalising their application for funding which will be assessed by an independent scientific review study ahead of the commencement of wider approvals, including ethics, and set up.</p><p>We will continue to monitor the impacts of the Order, including on mental health. Professor Louis Appleby, Chair of the National Suicide Prevention Strategy Advisory Group, has examined evidence for a large rise in suicides claimed by campaigners. His paper, which was published on 19 July 2024, concluded that the data do not support the claim that there has been a large rise in suicide in young gender dysphoria patients at the Tavistock clinic.</p><p>Some children and young people may be concerned by these changes. If they are already under the care of a Children and Young People’s mental health provider or the Child and Adolescent Mental Health Services, they can contact their team for advice. If they are not, their general practice team will be able to assess whether further referrals for mental health support are required. Patients can also be signposted to the advice on getting mental health support available on the NHS.UK website. Anyone in need of urgent support can contact NHS 111 and choose the mental health option, option two. Further details are available at the following link:</p><p><a href="https://www.nhs.uk/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/" target="_blank">https://www.nhs.uk/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/</a></p><p>Professor Appleby’s paper is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust-independent-report" target="_blank">https://www.gov.uk/government/publications/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust-independent-report</a></p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne grouped question UIN 109 87 question first answered 29/07/2024 13:55:40 answering member 1506 label Biography information for Andrew Gwynne
tabling member	4436 label Biography information for Cat Smith

1721327

registered interest
date	17/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gender Dysphoria: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will meet with (a) young trans young people and (b) their families to discuss the prescription of puberty blockers for the treatment of gender incongruence.
tabling member constituency	Lancaster and Wyre
tabling member printed	Cat Smith
uin	92
answer	answer is ministerial correction date of answer 29/07/2024 answer text <p>The emergency banning order limiting the sale or supply of puberty blockers against private or non-United Kingdom prescriptions allows a child under 18 years old, who was already on a course of treatment with Gonadotrophin-Releasing Hormone Analogues before 3 June 2024 from a UK based private or National Health Service provider, to continue to have them supplied. Those who were already on a course of treatment prescribed by an EEA or Switzerland registered prescriber can legally switch to a UK based prescriber to continue their treatment.</p><p>This government has committed to implementing the expert recommendations of the Cass Review to ensure that young people presenting to the NHS with gender dysphoria are receiving appropriate and high-quality care. That is why NHS England and the National Institue of Health and Care Research – the research arm of the department – are working together to commission a study into the potential benefits and harms of puberty suppressing hormones as a treatment option for children and young people with gender incongruence. The study team is now in place and are finalising their application for funding which will be assessed by an independent scientific review study ahead of the commencement of wider approvals, including ethics, and set up.</p><p>We recognise the value of engaging with representative groups and want to reset the relationship the department has with LGBT+ groups. My rt. Hon. Friend, the Secretary of State for Health and Social Care, will be meeting with LGBT+ stakeholders as soon as possible to hear directly about the health and care issues that are most important to them.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 29/07/2024 14:19:06 answering member 4444 label Biography information for Karin Smyth
tabling member	4436 label Biography information for Cat Smith

1721481

registered interest
date	17/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gender Dysphoria: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of the ban on puberty blockers on the mental health of trans patients under the age of 18.
tabling member constituency	Norwich South
tabling member printed	Clive Lewis
uin	109
answer	answer is ministerial correction date of answer 29/07/2024 answer text <p>The emergency banning Order, restricting the sale or supply of puberty blockers, was introduced by the previous Government. The Order enables those who were already on a course of treatment with Gonadotrophin-Releasing Hormone Analogues, before 3 June 2024 from a UK based private or National Health Service provider, to continue to have them supplied. Those who were already on a course of treatment prescribed by an EEA or Switzerland registered prescriber can legally switch to a UK based prescriber to continue their treatment.</p><p>The expert Cass Review, which is one of the most comprehensive reviews of gender identity services for children and young people to date, states that the rationale for early puberty suppressing hormones to treat gender dysphoria is unclear and the effects on cognitive and psychosexual development are unknown. This Government will always act in the interests of patient safety, which is why the Secretary of State signalled his intention to renew the Order and consult on a permanent ban (subject to the outcome of the ongoing judicial review).</p><p>We are committed to implementing the recommendations of the Cass Review to ensure that young people presenting to the NHS with gender dysphoria are receiving appropriate and high-quality care. That is why NHS England and the National Institute of Health and Care Research, the research arm of the Department, are working together to commission a study into the potential benefits and harms of puberty suppressing hormones as a treatment option for children and young people with gender incongruence. The study team is now in place and are finalising their application for funding which will be assessed by an independent scientific review study ahead of the commencement of wider approvals, including ethics, and set up.</p><p>We will continue to monitor the impacts of the Order, including on mental health. Professor Louis Appleby, Chair of the National Suicide Prevention Strategy Advisory Group, has examined evidence for a large rise in suicides claimed by campaigners. His paper, which was published on 19 July 2024, concluded that the data do not support the claim that there has been a large rise in suicide in young gender dysphoria patients at the Tavistock clinic.</p><p>Some children and young people may be concerned by these changes. If they are already under the care of a Children and Young People’s mental health provider or the Child and Adolescent Mental Health Services, they can contact their team for advice. If they are not, their general practice team will be able to assess whether further referrals for mental health support are required. Patients can also be signposted to the advice on getting mental health support available on the NHS.UK website. Anyone in need of urgent support can contact NHS 111 and choose the mental health option, option two. Further details are available at the following link:</p><p><a href="https://www.nhs.uk/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/" target="_blank">https://www.nhs.uk/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/</a></p><p>Professor Appleby’s paper is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust-independent-report" target="_blank">https://www.gov.uk/government/publications/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust-independent-report</a></p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne grouped question UIN 87 91 question first answered 29/07/2024 13:55:40 answering member 1506 label Biography information for Andrew Gwynne
tabling member	4500 label Biography information for Clive Lewis

1721483

registered interest
date	17/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gender Dysphoria: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department plans to take steps to monitor the potential impact of the ban on puberty blockers on (a) the mental health and (b) suicide rates among trans patients under the age of 18.
tabling member constituency	Norwich South
tabling member printed	Clive Lewis
uin	110
answer	answer is ministerial correction date of answer 29/07/2024 answer text <p>The emergency banning order, restricting the sale or supply of puberty blockers, was introduced by the previous government. The Order enables those who were already on a course of treatment with Gonadotrophin-Releasing Hormone Analogues, before 3 June 2024 from a UK based private or National Health Service provider, to continue to have them supplied. Those who were already on a course of treatment prescribed by an EEA or Switzerland-registered prescriber can legally switch to a UK based prescriber to continue their treatment.</p><p>We will continue to monitor the impact of the emergency order, including on mental health and suicide. All child deaths undergo a multi-agency review by a Child Death Overview Panel and that information is reported to the National Child Mortality Database. There is a monthly exercise by NHS officials to check the waiting list against NHS records to identify any deaths.</p><p>Professor Louis Appleby, Chair of the National Suicide Prevention Strategy Advisory Group, has examined evidence for a large rise in suicides claimed by campaigners. His paper, which was published on 19 July 2024, concluded that the data does not support the claim that there has been a large rise in suicide in young gender dysphoria patients at the Tavistock clinic.</p><p>This government has committed to implementing the expert recommendations of the Cass Review to ensure that young people presenting to the NHS with gender dysphoria are receiving appropriate and high-quality care. That is why NHS England and the National Institue of Health and Care Research – the research arm of the department – are working together to commission a study into the potential benefits and harms of puberty suppressing hormones as a treatment option for children and young people with gender incongruence. The study team is now in place and are finalising their application for funding which will be assessed by an independent scientific review study ahead of the commencement of wider approvals, including ethics, and set up.</p><p>Children and young people who are unable to access puberty blockers when they have previously done so are strongly advised to meet with their clinician. We expect clinicians to be working with impacted patients to consider what the best care for them is going forward. We understand some children and young people may be concerned or distressed by the changes. If they are already under the care of a Children and Young People’s mental health provider or Child and Adolescent Mental Health Services, they can contact their team for advice. If they are not, their general practice team will be able to assess whether further referrals for mental health support are required.</p><p>Professor Appleby’s paper is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust" target="_blank">https://www.gov.uk/government/publications/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust</a></p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 29/07/2024 14:01:29 answering member 4444 label Biography information for Karin Smyth
tabling member	4500 label Biography information for Clive Lewis

1721618

registered interest
date	17/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gender Dysphoria: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has a planned timetable for making the ban on administering puberty blockers to children permanent.
tabling member constituency	North Antrim
tabling member printed	Jim Allister
uin	333
answer	answer is ministerial correction date of answer 25/07/2024 answer text <p>The Secretary of State for Health and Social Care, has made clear his intention to consult on putting in place a permanent ban subject to the outcome of legal proceedings.</p><p>As this is matter is subject to legal proceedings, it would not be appropriate to comment further at this time.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 25/07/2024 08:59:25 answering member 4444 label Biography information for Karin Smyth previous answer version 163 answering member constituency Gorton and Denton answering member printed Andrew Gwynne answering member 1506 label Biography information for Andrew Gwynne
tabling member	5356